Oncotarget

Oncotarget Podcast
  • 5,0 (4)
  • НАУКА
  • ДВАЖДЫ В НЕДЕЛЮ

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed. Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

  1. Epigenetic Dysregulation of PDX1 Drives Prostate Cancer Progression

    -2 ДН.

    Epigenetic Dysregulation of PDX1 Drives Prostate Cancer Progression

    BUFFALO, NY – April 15, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer.” The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo from Howard University, Washington, DC. The team explored the role of the pancreatic and duodenal homeobox 1 (PDX1) gene in prostate cancer, with a focus on its epigenetic regulation and biological function. Their analysis identified PDX1 as differentially hypermethylated in prostate cancer tissues compared to normal prostate samples, alongside a paradoxical increase in protein expression in tumor tissues. Experiments in prostate cancer cell lines showed that PDX1 overexpression significantly enhanced cell proliferation and migration, while knockdown of PDX1 suppressed these tumor-associated behaviors. These findings point to a clear role for PDX1 in promoting aggressive cancer phenotypes. The work further shows that PDX1 regulates key metabolic, inflammatory, and epithelial–mesenchymal transition (EMT) pathways, including genes such as INSR, IGF1R, TWIST1, and SNAI1. Notably, these effects were more pronounced under high-glucose conditions, suggesting a link between metabolic state and prostate cancer progression. “Overall, our findings suggest that PDX1 plays a tumor-promoting role in human PCa cells by influencing expression of metabolites in insulin, inflammatory, and epithelial-mesenchymal transition (EMT) signaling pathways.” The authors conclude that PDX1 may represent a potential therapeutic target, particularly in the context of metabolic disorders such as obesity and diabetes, which are known to influence prostate cancer risk and progression. Their findings provide new insight into the interplay between epigenetics, metabolism, and tumor biology in prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28854 Correspondence to - Bernard Kwabi-Addo - bkwabi-addo@howard.edu Abstract video - https://www.youtube.com/watch?v=itYVsyXJJoE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28854 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PDX1, DNA methylation prostate cancer, shRNA knockdown, over-expression, glucose To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    3 мин.
  2. Cancer Care in Conflict Zones Remains Critically Neglected

    -4 ДН.

    Cancer Care in Conflict Zones Remains Critically Neglected

    BUFFALO, NY – April 13, 2026 – A new #review was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Cancer without borders: Policy frameworks for oncology care in humanitarian and conflict settings.” The study—led by corresponding author Pragnesh Parmar, along with Gunvanti Rathod from AIIMS Bibinagar, Telangana, India—brings together evidence from peer-reviewed studies, global health reports, and case examples from regions such as Gaza, Sudan, and Ukraine to examine the structural, ethical, and policy barriers limiting access to cancer care in humanitarian settings. Their findings show that oncology services are often excluded from emergency health priorities, resulting in delayed diagnosis, treatment interruptions, and reduced access to palliative care. The review further highlights that disrupted infrastructure, legal constraints, and fragmented policies disproportionately impact vulnerable populations—including women, children, and the elderly—who often present with advanced disease stages due to delays in care. “Addressing cancer in humanitarian contexts is not merely a technical challenge but a moral imperative.” The authors conclude that integrating oncology into humanitarian response frameworks is essential to ensure equitable access to care and improve outcomes for displaced populations. They emphasize the need for coordinated global strategies, including cross-border care models, tele-oncology, and policy reform, to address this critical gap in global health systems. DOI - https://doi.org/10.18632/oncotarget.28856 Correspondence to - Pragnesh Parmar - drprag@gmail.com; (ORCID: orcid.org/0000-0002-8402-8435) Abstract video - https://www.youtube.com/watch?v=zXlhIBZyJ6Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28856 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, cancer care, humanitarian crisis, tele-oncology, global health policy, oncology triage To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    2 мин.
  3. Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency

    10 АПР.

    Oncotarget Editorial Highlights Advances in Scientific Integrity and Publishing Transparency

    BUFFALO, NY – April 10, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on April 8, 2026, titled “Oncotarget: Past, Present and Future: Trends in the publishing industry.” Authored by the Scientific Integrity Office at Oncotarget, the editorial comprehensively analyzes the journal’s evolving approach to scientific integrity. It addresses historical challenges in scholarly publishing and discusses the necessity of modern image forensics tools to meet the most rigorous standards of scientific integrity. The Scientific Integrity Office describes how advances in digital technologies—particularly image forensics tools such as ImageTwin and analytical platforms like Argos—have transformed the ability to detect problematic data and analyze the quality of published research. The editorial emphasizes that the lack of adequate image tools in the “pre-tools” era limited journals’ ability to detect image-related issues, underscoring the importance of recent technological advancements. It also highlights that Argos provides a good opportunity to obtain a more objective picture across different journals in both the pre- and post-tools era. Looking forward, Oncotarget advocates indexes for broader adoption of independent analytical and AI-based tools in journal evaluation. In the public interest, it also encourages open discussion of how indexes select, deselect, and reevaluate journals. DOI - https://doi.org/10.18632/oncotarget.28852 Correspondence to - Scientific Integrity Office - scientificintegrityoffice@impactjournals.com Introduction video - https://www.youtube.com/watch?v=hgxvr2Q_ZPM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28852 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - Scientific Integrity, Academic Publishing, Open Access, Peer Review, Research To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    2 мин.
  4. CREB5: A Master Regulator of Stem Cell-Like Programs in Prostate Cancer Progression

    7 АПР.

    CREB5: A Master Regulator of Stem Cell-Like Programs in Prostate Cancer Progression

    Androgen receptor (AR) signaling has long been the central driver of prostate cancer progression and the primary target of therapies for advanced disease. Yet, a significant subset of tumors either fail to respond or develop resistance, often by switching to AR-independent programs that resemble basal or stem cell-like states. Understanding what drives these aggressive, therapy-resistant phenotypes is a critical challenge in oncology. A research paper, titled “CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer” was published in Volume 17 of Oncotarget by a multi-institutional team of researchers, identifies a key molecular regulator of this process and reveals how it promotes tumor progression. Full blog - https://www.oncotarget.org/2026/04/07/creb5-a-master-regulator-of-stem-cell-like-programs-in-prostate-cancer-progression/ Paper DOI - https://doi.org/10.18632/oncotarget.28826 Correspondence to - Emmanuel S. Antonarakis - anton401@umn.edu, Justin Hwang - jhwang@umn.edu Abstract video - https://www.youtube.com/watch?v=Zywrj5hV4ho Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28826 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, prostate cancer, CREB5, basal-like, stem cell-like, AP-1 transcription factors To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    11 мин.
  5. Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers

    7 АПР.

    Adjuvant PD-1/PD-L1 Inhibitors Show Efficacy but Highlight Safety Considerations in Solid Cancers

    BUFFALO, NY – April 7, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.” Led by first author Maryam Aleid from Imam Abdulrahman Bin Faisal University, and corresponding author Dhai Almuteri from King Fahad Specialist Hospital, the researchers evaluated 13 randomized controlled trials involving 9,850 patients to assess the efficacy and safety of PD-1 and PD-L1 inhibitors as adjuvant therapy following tumor resection. The analysis demonstrated that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies. The study also identified a reduction in recurrence and metastasis risk, supporting the role of these therapies in early-stage cancer management. At the same time, variability across tumor types suggests that benefits may differ depending on cancer subtype and patient population. “Adjuvant PD-1 and PD-L1 inhibitors improve disease-free and distant metastasis-free survival in selected patients with high-risk solid tumors.” In terms of safety, the findings highlight an increased incidence of adverse events associated with PD-1/PD-L1 inhibitors, including fatigue, nausea, pruritus, and hypothyroidism, emphasizing the importance of careful monitoring during treatment. The authors conclude that while PD-1/PD-L1 inhibitors offer meaningful benefits in reducing recurrence and metastasis in high-risk solid tumors, the clinical benefit must be balanced against higher toxicity rates. Future research is needed to refine patient selection, evaluate long-term survival outcomes, and better understand differences across tumor types to optimize the use of these therapies in clinical practice. DOI - https://doi.org/10.18632/oncotarget.28855 Correspondence to - Dhai Almuteri - d.almuteri@qu.edu.sa Abstract video - https://www.youtube.com/watch?v=4Ce07bHfjB4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28855 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PD-1, PD-L1, adjuvant immunotherapy, solid tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    3 мин.
  6. Bibliometric Mapping Reveals the Evolution of Glioma Classification Research

    6 АПР.

    Bibliometric Mapping Reveals the Evolution of Glioma Classification Research

    BUFFALO, NY – April 6, 2026 – A new #review was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.” Led by first and corresponding author Kayode Ahmed from The University of Texas MD Anderson Cancer Center, and Juan E. Núñez-Ríos from Universidad Panamericana, the study uses bibliometric network analysis to map how glioma classification research has evolved across clinical, molecular, and social domains. The authors analyzed Web of Science data using direct citation networks and applied main path analysis, key route analysis, and K-core analysis to identify influential papers, critical routes, and densely connected thematic clusters. The network comprised 46,204 nodes and 231,432 arcs, highlighting the prominent role of DNA methylation profiling in molecular biomarker-based classification models. The authors also found that advanced imaging and molecular techniques were key drivers of the field, while the subset of glioma classification studies that incorporate social factors remained relatively scarce. Their analysis, therefore, points not only to the major intellectual structure of the literature but also to a thematic gap in how social determinants are represented in glioma classification research. “Through quantitative network analysis complemented by narrative interpretation, we uncovered patterns and substructures that offer deep insights into the evolving research landscape.” The authors conclude that their framework offers a more integrative view of glioma classification research than approaches centered only on citation counts or h-index–style metrics. By identifying the evolutionary logic of the field and the limited but notable presence of social factors, the study suggests future glioma classification models may benefit from incorporating clinical, molecular, and social dimensions more explicitly. DOI - https://doi.org/10.18632/oncotarget.28851 Correspondence to - Kayode Ahmed - kmahmed@mdanderson.org Abstract video - https://www.youtube.com/watch?v=v8h2z3eEMFM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28851 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, glioma research, social network analysis, socio-clinical domains, web of science, networks To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    2 мин.
  7. The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells

    31 МАР.

    The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells

    BUFFALO, NY – March 31, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” Led by Michael R. Booth, Laurence Booth, and Jane L. Roberts from Virginia Commonwealth University, with corresponding author Paul Dent from the same institution and John M. Kirkwood from the University of Pittsburgh Cancer Institute, the study examines how aramchol interacts with regorafenib and metformin to kill tumor cells, particularly patient-derived uveal melanoma (UM) cells and cholangiocarcinoma cells. The authors report that aramchol, regorafenib, and metformin interact to enhance tumor cell killing, with the strongest effects seen when metformin is added to aramchol plus regorafenib. In patient-derived UM cells and LD-1 cholangiocarcinoma cells, the three-drug combination increased autophagosome formation and autophagic flux, while knockdown of Beclin1, ATG5, or LAMP2 reduced autophagosome and autolysosome formation and lowered cell killing. The study also found that BID contributes to the lethal response, supporting a multifactorial mechanism involving macroautophagy and death-receptor signaling. “Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.” The authors also note that while SCD1 knockdown increased baseline tumor cell death, it did not replicate the full anticancer effects of aramchol, suggesting additional molecular targets contribute to its activity. They emphasize the need for further in vivo studies to evaluate the therapeutic potential of this combination in metastatic uveal melanoma, particularly in liver-targeted disease. DOI - https://doi.org/10.18632/oncotarget.28861 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Abstract video - https://www.youtube.com/watch?v=lmX_c2e_-HY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28861 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, ER stress, aramchol, regorafenib, BID To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    2 мин.
  8. Predicting Colorectal Cancer Survival: How Machine Learning Combines Clinical and Biological Clues

    25 МАР.

    Predicting Colorectal Cancer Survival: How Machine Learning Combines Clinical and Biological Clues

    Colorectal cancer (CRC) ranks among the most common and lethal cancers worldwide, accounting for approximately 10% of all cancer diagnoses. While advances in prevention and treatment have improved outcomes, predicting which patients will survive remains a complex challenge—one that depends on an intricate interplay between molecular biology and clinical factors. A research paper, titled “Machine learning-based survival prediction in colorectal cancer combining clinical and biological features” was published in Volume 16 of Oncotarget by an international team of researchers, demonstrating how machine learning can integrate these two domains to achieve highly accurate survival predictions. The team’s investigation demonstrates that combining clinical features—such as pathological stage, age, and lymph node status—with biological markers—including the E2F8 gene and hsa-miR-495-3p—can significantly improve the ability to predict patient survival. Full blog - https://www.oncotarget.org/2026/03/25/predicting-colorectal-cancer-survival-how-machine-learning-combines-clinical-and-biological-clues/ Paper DOI - https://doi.org/10.18632/oncotarget.28783 Correspondence to - Lucas M. Vieira - lvieira@health.ucsd.edu Abstract video - https://www.youtube.com/watch?v=cy7UL5ZUKuI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28783 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, colorectal cancer, machine learning, feature selection, non-coding RNAs, genes To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

    9 мин.
См. все (504)

5
из 5
Оценок: 4

Об этом подкасте

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed. Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Информация

  • Автор
    Oncotarget Podcast
  • Годы выхода
    2017 - 2026
  • Выпуски
    504
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © All rights reserved
  • Сайт подкаста
    Oncotarget